ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CEO Nikhil Lalwani sold 33,481 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the sale, the chief executive officer now owns 370,378 shares in the company, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
ANI Pharmaceuticals Stock Up 2.6 %
Shares of NASDAQ:ANIP opened at $59.39 on Thursday. ANI Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The business's 50-day moving average is $58.32 and its 200-day moving average is $60.76. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -107.98 and a beta of 0.71.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.25. The firm had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company's revenue was up 12.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.05 earnings per share. Equities research analysts predict that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.
Institutional Inflows and Outflows
After New Years, price goes back up 4,800%
From StocksToTrade | Ad
When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!
Click here to review Tim’s special Holiday offer before it’s too late.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Innealta Capital LLC acquired a new position in shares of ANI Pharmaceuticals during the second quarter valued at about $65,000. Ridgewood Investments LLC bought a new stake in ANI Pharmaceuticals in the 2nd quarter valued at about $85,000. SG Americas Securities LLC acquired a new position in ANI Pharmaceuticals during the 1st quarter worth approximately $106,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock worth $177,000 after buying an additional 579 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth $207,000. 76.05% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on the stock. Raymond James raised their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research note on Wednesday, September 18th. Piper Sandler initiated coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They set an "overweight" rating and a $68.00 target price for the company. StockNews.com lowered ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, September 7th. HC Wainwright restated a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Finally, Truist Financial upped their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a report on Tuesday, October 22nd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $77.33.
Get Our Latest Research Report on ANIP
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
